Skip to content
CancerIndex

Publication

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Authors not recorded

J Clin Oncol2006PMID 16954519stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (13)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 13

Curated evidence

Evidence citing this paper (9)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
16954519
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–9 of 9 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
KIT C809G1
ImatinibGastrointestinal Stromal TumorPredictiveCSupports Resistance3accepted
EID2920

147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors wer… (full text at CIViC)

PMID 16954519 · Heinrich et al., 2006 · Open in CIViC

civic
KIT D816H1
ImatinibGastrointestinal Stromal TumorPredictiveCSupports Resistance3accepted
EID2923

147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors wer… (full text at CIViC)

PMID 16954519 · Heinrich et al., 2006 · Open in CIViC

civic
KIT D820A1
ImatinibGastrointestinal Stromal TumorPredictiveCSupports Resistance3accepted
EID2921

147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors wer… (full text at CIViC)

PMID 16954519 · Heinrich et al., 2006 · Open in CIViC

civic
KIT D820G1
ImatinibGastrointestinal Stromal TumorPredictiveCSupports Resistance3accepted
EID2922

147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors wer… (full text at CIViC)

PMID 16954519 · Heinrich et al., 2006 · Open in CIViC

civic
KIT N822K1
ImatinibGastrointestinal Stromal TumorPredictiveCSupports Resistance3accepted
EID2918

147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors wer… (full text at CIViC)

PMID 16954519 · Heinrich et al., 2006 · Open in CIViC

civic
KIT T670I1
ImatinibGastrointestinal Stromal TumorPredictiveCSupports Resistance3accepted
EID2924

147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors wer… (full text at CIViC)

PMID 16954519 · Heinrich et al., 2006 · Open in CIViC

civic
KIT V654A1
ImatinibGastrointestinal Stromal TumorPredictiveDSupports Resistance3accepted
EID249

KIT V654A results in imatinib resistance in GIST patient-derived cell lines.

PMID 16954519 · Heinrich et al., 2006 · Open in CIViC

civic
KIT Y823D1
ImatinibGastrointestinal Stromal TumorPredictiveCSupports Resistance3accepted
EID2919

147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors wer… (full text at CIViC)

PMID 16954519 · Heinrich et al., 2006 · Open in CIViC

civic
PDGFRA D842V1
ImatinibGastrointestinal Stromal TumorPredictiveBSupports Resistance4accepted
EID16

While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib.

PMID 16954519 · Heinrich et al., 2006 · Open in CIViC

civic